# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-27
**æ›´æ–°æ—¶é—´**: 2026-01-28 03:45
**æ–°é—»æ•°é‡**: 102

---

## ä»Šæ—¥æ¦‚è§ˆ

## ðŸ“Š AI æ™ºèƒ½åˆ†æž

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºŽç›‘ç®¡å®¡æ‰¹ä¸Žä¸´åºŠè¯•éªŒè¿›å±•ã€‚FDAæ‰¹å‡†äº†å¼ºç”ŸDarzalex Fasproè”åˆç–—æ³•ç”¨äºŽæ–°è¯Šæ–­å¤šå‘æ€§éª¨é«“ç˜¤ï¼ŒåŒæ—¶æœ‰æ¡ä»¶è§£é™¤äº†IntelliaåŸºå› ç¼–è¾‘ç–—æ³•çš„ä¸€é¡¹ä¸´åºŠæš‚åœã€‚æ­¤å¤–ï¼Œè¯ºå’Œè¯ºå¾·å£æœWegovyä¸Šå¸‚åˆæœŸè¡¨çŽ°å¼ºåŠ²ï¼Œè€ŒBausch Healthçš„XifaxanåŽç»§è¯ç‰©IIIæœŸè¯•éªŒå¤±è´¥åˆ™å¸¦æ¥æŒ«æŠ˜ã€‚

### ðŸ”¥ é‡ç‚¹æ–°é—»

**4. FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAæ‰¹å‡†äº†å¤šå‘æ€§éª¨é«“ç˜¤ä¸€çº¿æ²»ç–—çš„é‡è¦æ–°è”åˆç–—æ³•ï¼Œå°†ç›´æŽ¥å½±å“ä¸´åºŠå®žè·µå’Œå¸‚åœºç«žäº‰æ ¼å±€ã€‚

**3. FDA lifts hold on an Intellia CRISPR drug trial** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAè§£é™¤å¯¹Intellia CRISPRåŸºå› ç¼–è¾‘ç–—æ³•ä¸€é¡¹å…³é”®IIIæœŸè¯•éªŒçš„æš‚åœï¼Œæ˜¯åŸºå› æ²»ç–—é¢†åŸŸçš„é‡è¦ç›‘ç®¡è¿›å±•ã€‚

**11. Novo's Wegovy pill launch wows with strong early uptake: analysts** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æž
   - è¯ºå’Œè¯ºå¾·å£æœç‰ˆWegovyä¸Šå¸‚åˆæœŸå¤„æ–¹é‡è¡¨çŽ°å¼ºåŠ²ï¼Œé¢„ç¤ºç€å£æœGLP-1è¯ç‰©å¯èƒ½é‡å¡‘å·¨å¤§çš„å‡è‚¥è¯å¸‚åœºã€‚

**7. Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - Bausch Healthæ ¸å¿ƒäº§å“Xifaxançš„åŽç»§è¯ç‰©IIIæœŸå¤±è´¥ï¼Œå¯¹å…¶äº§å“ç®¡çº¿æ›´æ–°å’Œæœªæ¥æ”¶å…¥æž„æˆé‡å¤§æ‰“å‡»ã€‚

**2. Genmab halts enrollment for cancer drug from ProfoundBio buyout** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - Genmabæš‚åœå…¶18äº¿ç¾Žå…ƒæ”¶è´­æ‰€å¾—ç™Œç—‡å€™é€‰è¯ç‰©çš„æ—©æœŸè¯•éªŒå…¥ç»„ï¼Œè¡¨æ˜Žèµ„äº§æ•´åˆåŽä¸´åºŠå¼€å‘é‡æŒ«ã€‚

### ðŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): åŸºå› ç¼–è¾‘ï¼ˆIntelliaï¼‰ã€æŠ—è¡°è€åŸºå› ç–—æ³•ï¼ˆLife Biosciencesï¼‰å’Œæ–°åž‹å…ç–«è¯ç‰©ï¼ˆTRex Bioï¼‰ç­‰é¢†åŸŸæœ‰ç ”å‘è¿›å±•ï¼Œä¸­å›½åœ¨æ—©æœŸè¯ç‰©ç ”å‘æ–¹é¢çš„ä¼˜åŠ¿é¢„è®¡å°†æŒç»­ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): å…³é”®IIIæœŸè¯•éªŒç»“æžœé¢‘å‡ºï¼ŒåŒ…æ‹¬Bausch Healthçš„å¤±è´¥å’ŒRoche GLP-1è¯ç‰©çš„æ–°æ•°æ®ã€‚åŒæ—¶ï¼ŒGenmabæš‚åœäº†å…¶æ”¶è´­æ‰€å¾—èµ„äº§çš„æ—©æœŸè¯•éªŒå…¥ç»„ã€‚

### ðŸ”® æ˜Žæ—¥å…³æ³¨

å…³æ³¨FDA/MHRA/Health Canadaå…³äºŽè‰¯å¥½ä¸´åºŠå®žè·µã€ç”Ÿç‰©ç­‰æ•ˆæ€§å’Œè¯ç‰©è­¦æˆ’çš„è”åˆç ”è®¨ä¼šï¼ˆ06/02/2026ï¼‰ï¼Œå…¶è®¨è®ºå†…å®¹å¯èƒ½é¢„ç¤ºæœªæ¥ç›‘ç®¡è¶‹åŠ¿ã€‚åŒæ—¶ï¼Œéœ€ç•™æ„æ¬§ç›Ÿä¸Žå°åº¦æ—¨åœ¨å–æ¶ˆè¯å“å‡ºå£å…³ç¨Žçš„è‡ªç”±è´¸æ˜“åå®šè°ˆåˆ¤è¿›å±•ï¼Œè¿™å¯èƒ½å½±å“å…¨çƒä¾›åº”é“¾æ ¼å±€ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 40 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## ç»¼åˆ | ç»¼åˆ

### ðŸ‡ºðŸ‡¸ Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 09:13
- **é‡è¦æ€§**: â­â­â­â­â­

> Juggling a mix of customer demand and new regulations, Recipharm has built out a new facility in Bengaluru, India, to produce nonbacterial beta-lactam tablets. By commissioning the plant, Recipharm says it has lassoed up a â€œmajor partnershipâ€ with an unnamed, â€œleading innovative biopharmaceutical companyâ€ to help produce the partner's non-bacterial beta-lactam tablets.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/fda-winds-changing-recipharm-debuts-purpose-built-plant-beta-lactam-drugs)

---

### ðŸ‡ºðŸ‡¸ Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:08
- **é‡è¦æ€§**: â­â­â­

> A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the companyâ€™s bread-and-butter Xifaxanâ€”a setback that leaves a $2 billion hole in its growth plan.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/bausch-healths-2b-pursuit-xifaxan-successor-hits-wall-phase-3-failure)

---

### ðŸ‡ºðŸ‡¸ EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 11:13
- **é‡è¦æ€§**: â­â­

> Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the European Union and India to carry their deal across the finish line.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/eu-looks-knock-out-pharmaceutical-export-tariffs-sweeping-free-trade-pact-india)

---

### ðŸ‡ºðŸ‡¸ Novo's Wegovy pill launch wows with strong early uptake: analysts

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 09:42
- **é‡è¦æ€§**: â­â­

> In the second week of oral Wegovyâ€™s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than that of either injectable Wegovy or Eli Lilly's Zepbound during the first two weeks of their respective rollouts, the analyst team noted.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says)

---

### ðŸ‡ºðŸ‡¸ Fierce Pharma Asiaâ€”Astellas CEO's BD plan; Takeda's US layoffs; Chugai's chase for name recognition

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:31
- **é‡è¦æ€§**: â­â­

> Astellas CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. Chugai's CEO is seeking name recognition as the Roche unit looks for more external partners. And more.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/astellas-ceo-bd-plan-takeda-us-layoffs-chugai-chase-name-recognition)

---

### ðŸ‡ºðŸ‡¸ Biosimilar execs optimistic about future for US biosims as Sandoz locks in on 'golden decade' to come

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 17:07
- **é‡è¦æ€§**: â­â­

> Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:05
- **é‡è¦æ€§**: â­â­

> The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 14:27
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 17:40
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:14
- **é‡è¦æ€§**: â­â­

> Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Teva taps â€˜SNLâ€™ alum Will Forte to join Huntingtonâ€™s disease awareness push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 15:42
- **é‡è¦æ€§**: â­

> Following in the footsteps of Phathom Pharmaceuticals' and Allergan Aestheticsâ€™ own partnerships with â€œSaturday Night Liveâ€ stars, Teva Pharmaceuticals is turning to a famous funnyman to tackle a not-so-funny topic.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/teva-taps-snl-alum-will-forte-join-huntingtons-disease-awareness-push)

---

### ðŸ‡ºðŸ‡¸ Arcutis, Kowa part ways on US marketing partnership for Zoryve

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 11:15
- **é‡è¦æ€§**: â­

> The companies had committed to a five-year partnership in July 2024, in which Kowa agreed to promote the topical treatment to primary care physicians to extend the med's reach beyond dermatologists.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/arcutis-kowa-cut-ties-two-years-us-marketing-partnership-arcutis-topical-zorvye)

---

### ðŸ‡ºðŸ‡¸ Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:55
- **é‡è¦æ€§**: â­

> As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:17
- **é‡è¦æ€§**: â­

> Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Trump administration rolls out 15 more high-profile drugs for IRA price negotiations

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 17:14

> Even as the Trump administration works to implement its "most favored nation" pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/trump-administration-rolls-out-15-more-high-profile-drugs-ira-price-negotiations)

---

### ðŸ‡ºðŸ‡¸ China regulators suspend sale of Sun Pharma's dementia med after site inspection

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 11:13

> Chinaâ€™s National Medical Products Administration suspended the import, sale and use of Sun's rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/chinese-regulators-suspend-sale-sun-pharmas-dementia-med-after-site-inspection)

---

### ðŸ‡ºðŸ‡¸ Servier delivers 16% revenue jump, firming up â‚¬10B ambition by 2030

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 10:09

> After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved â€œone important step closerâ€ to achieving an ambitious goal for 2030.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/servier-delivers-16-revenue-jump-firming-eu10b-ambition-2030)

---

### ðŸ‡ºðŸ‡¸ Pfizer retains top spot in vaccine maker rankings as Sanofi's slide sparks 'code red' call

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 10:06

> Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck &amp; Co. and Moderna to complete an unchanged top three from the last edition of the survey. But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/pfizer-retains-top-spot-vaccine-rankings-sanofis-slide-sparks-code-red-call)

---

### ðŸ‡ºðŸ‡¸ Siegfried extends M&amp;A streak, gaining 3 sites from SK Capital and advancing US onshoring aims

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 09:47

> Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience. With the deals, Siegfried gains API sites in Wilmington, Delaware; Athens, Georgia; and Australia.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/siegfried-continues-its-ma-splurge-gaining-3-sites-sk-capital)

---

### ðŸ‡ºðŸ‡¸ Catalent moves to wind down operations at EU cell therapy manufacturing hub

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 15:01

> Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell therapy manufacturing operations in the town.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/catalent-moves-wind-down-operations-eu-cell-therapy-manufacturing-hub)

---

### ðŸ‡ºðŸ‡¸ New rules, higher stakes: Biopharma plays the long game in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 13:20

> While 2025 was dedicated to â€œunderstanding a little bit more about the rules of this game that weâ€™re playing,â€ 2026 is all about being active players in the game, McKinsey senior partner Greg Graves said Jan. 13 at Fierce JPM Week.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/biotech/new-rules-higher-stakes-biopharma-plays-long-game-2026)

---

### ðŸ‡ºðŸ‡¸ Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-26 10:28

> With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. But the road to market leadership is growing more complex as the two AstraZeneca-partnered brands move into earlier lines of therapy while facing intensifying competition.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/daiichi-sankyo-navigates-complexity-success-enhertu-datroway-push-market-dominance)

---

### ðŸ‡ºðŸ‡¸ Lilly battles weight stigma in short film centering obesity conversation on health, not appearance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:52

> GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not)

---

### ðŸ‡ºðŸ‡¸ RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio shot guidance on podcast

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:19

> The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast â€œWhy Should I Trust You?â€ to answer exactly that.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/new-acip-chair-talks-established-science-polio-vaccine-uncertainty-and-individual-autonomy)

---

### ðŸ‡ºðŸ‡¸ ST Pharm inks $56M deal to produce API for a US biotech

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:15

> ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/st-pharm-inks-56m-deal-produce-apis-us-biotech)

---

### ðŸ‡ºðŸ‡¸ Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 07:18

> Plotting a challenge to Regeneronâ€™s blockbuster Eylea, Ocular Therapeutix has hired â€œa key architectâ€ of its rivalâ€™s launch to head its commercial team.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/ocular-drafts-eylea-launch-architect-lead-attack-regenerons-blockbuster)

---

### ðŸ‡ºðŸ‡¸ JPM26: Sunshine, AI and the deals that weren't

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:09

> Fierceâ€™s Zoey Becker, Angus Liu and Gabrielle Masson unpack the key topics and trends that stood out at this yearâ€™s J.P. Morgan Healthcare Conference.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/recapping-2026-jp-morgan-healthcare-conference)

---

### ðŸ‡ºðŸ‡¸ Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:19

> While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius)

---

### ðŸ‡ºðŸ‡¸ Invivyd teams up with Olympic skier Lindsey Vonn for antibody education

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54

> As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education)

---

### ðŸ‡ºðŸ‡¸ STAT+: New startup to develop a GLP-1 drug for addiction

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:40

> And other biotech news brought to you by The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Roche moves obesity drug to pivotal trials after mid-stage success

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 08:08

> Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 21:11

> The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Launch of Wegovy pill looks to be going strong so far

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:30

> And more biotech news brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 17:19

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Insurers blame drugmakers, hospitals for high prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 15:26

> Plus more biotech news updates, brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Health insurance execs shift blame for costly, confusing health care system

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 20:11

> Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: France rebuffs Trump over drug-pricing boast

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 15:58

> And more biotech news from The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 14:26

> Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 09:30

> Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Novo strikes deal for diabetes cell therapies

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:53

> And other biotech news, brought to you by The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ðŸ‡ºðŸ‡¸ Genmab halts enrollment for cancer drug from ProfoundBio buyout

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 11:31
- **é‡è¦æ€§**: â­â­â­â­â­

> Genmab has stopped enrolling patients for an early-stage trial of a cancer candidate it obtained in its $1.8 billion acquisition of US-China biotech ProfoundBio. The Phase 1/2 study of GEN1286 was meant to enroll 260 ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/)

---

### ðŸ‡ºðŸ‡¸ FDA lifts hold on an Intellia CRISPR drug trial

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 16:59
- **é‡è¦æ€§**: â­â­â­â­

> Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/)

---

### ðŸ‡ºðŸ‡¸ FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 15:52
- **é‡è¦æ€§**: â­â­â­

> The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/fda-lifts-hold-on-one-of-two-phase-3-gene-editing-studies-by-intellia/)

---

### ðŸ‡ºðŸ‡¸ Roche, trailing in obesity, showcases new data for GLP-1 shot

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 16:31
- **é‡è¦æ€§**: â­â­

> A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/)

---

### ðŸ‡ºðŸ‡¸ An immune drug developer raises $50M to finance its eczema drug testing

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 15:53
- **é‡è¦æ€§**: â­â­

> TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/trex-bio-series-b-extension-atopic-dermatitis/810617/)

---

### ðŸ‡ºðŸ‡¸ Chinaâ€™s edge in early-stage drugmaking â€˜likely to persist,â€™ Pitchbook says

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 19:15
- **é‡è¦æ€§**: â­â­

> The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/china-biotech-drug-licensing-trends-pitchbook-cell-gene-therapy/810478/)

---

### ðŸ‡ºðŸ‡¸ Biotech investor Cormorant secures $150M for another SPAC deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 14:43
- **é‡è¦æ€§**: â­â­

> Amid a rebound in SPAC activity, the prolific &ldquo;crossover&rdquo; investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/cormorant-helix-iii-spac-deal-biotech-merger-ipo/810436/)

---

### ðŸ‡ºðŸ‡¸ The formula for biotech success in 2026: Confidence, resilience and funding

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 14:00
- **é‡è¦æ€§**: â­â­

> Survey of 260+ biotech leaders assesses the biotech climate, trends, opportunities and risks.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/spons/the-formula-for-biotech-success-in-2026-confidence-resilience-and-funding/810037/)

---

### ðŸ‡ºðŸ‡¸ FDA greenlights Life Biosciences' gene therapy study to rewind the age of cells

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 13:00
- **é‡è¦æ€§**: â­â­

> One of the biggest theories about the cause of aging, and how to slow and potentially even reverse it, is about to be put to the test. Life Biosciences, a biotech startup co-founded by Harvard ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/exclusive-fda-greenlights-gene-therapy-study-to-rewind-the-age-of-cells/)

---

### ðŸ‡ºðŸ‡¸ UK-US biotech investor Epidarex raises $145M for fourth fund

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 07:00
- **é‡è¦æ€§**: â­â­

> Epidarex Capital raised $145 million in the first close of its fourth fund as the biotech investor searches for the next generation of standout science in overlooked research corridors of the UK and US. ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/uk-us-biotech-investor-epidarex-raises-145m-for-fourth-fund/)

---

### ðŸ‡ºðŸ‡¸ First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-24 11:00
- **é‡è¦æ€§**: â­â­

> Welcome back to another edition of Endpoints Weekly. Though we may have had a short week with Martin Luther King Jr. Day, the news kept on coming. Letâ€™s dive in. We had a little bit ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/first-movers-respond-to-herding-biomarin-vets-start-new-biotech-gsk-buys-rapt-therapeutics-and-more/)

---

### ðŸ‡ºðŸ‡¸ ACIP members depict diverging goals after schedule change

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 18:24
- **é‡è¦æ€§**: â­â­

> Fresh off health officialsâ€™ sweeping remake of the US childhood vaccine schedule, two members of a key CDC panel are depicting different versions of the committeeâ€™s work moving forward. Comments made this week by Robert ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/acip-members-depict-diverging-goals-after-schedule-change/)

---

### ðŸ‡ºðŸ‡¸ Cardiff execs depart as company drops mixed Phase 2 data

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 18:22
- **é‡è¦æ€§**: â­

> Shares {$CRDF} of Cardiff Oncology fell more than 30% after the biotech disclosed mixed Phase 2 data and announced the departure of two of its top executives. San Diego-based Cardiff

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/cardiff-execs-depart-as-company-drops-mixed-phase-2-data/)

---

### ðŸ‡ºðŸ‡¸ Insilicoâ€™s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 15:40
- **é‡è¦æ€§**: â­

> Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/insilicos-latest-deal-is-a-120m-cardiometabolic-drug-discovery-pact-with-qilu-pharma/)

---

### ðŸ‡ºðŸ‡¸ AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 14:31
- **é‡è¦æ€§**: â­

> Plus, news about Vial, Skyhawk and Gimv: AstraZeneca stops cardio drug: The UK pharma giant has terminated a Phase 1 of an oral cardio drug candidate called AZD0233, according ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/astrazeneca-ends-work-on-cardio-drug-lisata-and-qilu-terminate-deal/)

---

### ðŸ‡ºðŸ‡¸ Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 13:56
- **é‡è¦æ€§**: â­

> Boehringer Ingelheim will pair up with Simcere Pharmaceutical in one of the hottest targets in immunology. For â‚¬42 million ($50 million) upfront, the German pharma will tap into Simcere's preclinical TL1AxIL-23p19 bispecific antibody for inflammatory ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/boehringer-ingelheim-gets-an-ibd-bispecific-from-shanghai-based-simcere/)

---

### ðŸ‡ºðŸ‡¸ Updated: Rocheâ€™s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 12:09
- **é‡è¦æ€§**: â­

> Rocheâ€™s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma said Tuesday. ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/roches-obesity-shot-posts-decent-weight-loss-in-mid-stage-test-heads-to-phase-3/)

---

### ðŸ‡ºðŸ‡¸ TRexBio gets another $50M to bring more Treg candidates into the clinic

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 12:00
- **é‡è¦æ€§**: â­

> Bay Area startup TRexBio has bolstered its 2024 Series B with an additional $50 million to fund the biotech's clinical development in the burgeoning Treg space. The biotech, founded in 2018 by SV Health Investors ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/)

---

### ðŸ‡ºðŸ‡¸ Sarepta touts three-year Duchenne gene therapy data after patient deaths

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 16:17
- **é‡è¦æ€§**: â­

> Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial. The data come after a tumultuous year ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/sarepta-touts-three-year-duchenne-gene-therapy-data-after-patient-deaths/)

---

### ðŸ‡ºðŸ‡¸ EU kicks off one-year pilot to expedite multinational trials

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 19:24
- **é‡è¦æ€§**: â­

> The European Union unveiled details of a pilot project that aims to accelerate the timeline for starting new multinational clinical trials. The voluntary pilot, called FASTâ€‘EU, will feature a maximum 10â€‘week (70â€‘day) timeline from drugmaker ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/eu-kicks-off-one-year-pilot-to-expedite-multinational-trials/)

---

### ðŸ‡ºðŸ‡¸ Sarepta, battling slowing sales, claims Duchenne gene therapyâ€™s impact grows with time

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 16:46

> On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help &ldquo;rebalance the discussion&rdquo; surrounding Elevidys.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/)

---

### ðŸ‡ºðŸ‡¸ Express Scripts considering settlement in FTC insulin price lawsuit

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 14:02

> The antitrust agency paused its lawsuit against the pharmacy benefit manager while the two discuss a proposed consent agreement.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/cigna-express-scripts-ftc-insulin-pricing-settlement-talks/810452/)

---

### ðŸ‡ºðŸ‡¸ The crucial role of raw material selection for success in cell therapy manufacturing

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 10:00

> &nbsp;Why raw materials make or break cell therapy manufacturing success.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/spons/the-crucial-role-of-raw-material-selection-for-success-in-cell-therapy-manu/810179/)

---

### ðŸ‡ºðŸ‡¸ From detection to prevention: How sponsored testing can transform patient outcomes

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-26 10:00

> Diagnostic testing has long laid the groundwork for medical decision-making. &nbsp;

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/spons/from-detection-to-prevention-how-sponsored-testing-can-transform-patient-o/809935/)

---

### ðŸ‡ºðŸ‡¸ Updated: CMS picks Lillyâ€™s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 22:26

> Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act. Eli Lillyâ€™s diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. For the ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/cms-picks-lillys-trulicity-for-third-round-of-medicare-negotiations/)

---

### ðŸ‡ºðŸ‡¸ Hospitals could earn more for buying US-made drugs, CMS proposes

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 20:05

> The Trump administration's Centers for Medicare &amp; Medicaid Services is looking to incentivize hospitals to buy more domestically-produced drugs. Under a proposed rule, hospitals purchasing more than 50% of domestic-made essential ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/hospitals-could-earn-more-for-buying-us-made-drugs-cms-proposes/)

---

### ðŸ‡ºðŸ‡¸ UnitedHealth projects lower revenue in 2026 as it resets its business

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 18:11

> UnitedHealth Groupâ€™s turnaround plan to trade membership for improved profit margins will result in lower revenue in 2026, as the healthcare giant attempts to recover from a disastrous period of setbacks that ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/unitedhealth-projects-lower-revenue-in-2026-as-it-resets-its-business/)

---

### ðŸ‡ºðŸ‡¸ Virtual womenâ€™s health company Wisp buys TBD Health

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-27 14:00

> Wisp, a womenâ€™s telehealth company, bought sexual healthcare startup TBD Health, as virtual care companies look to become more comprehensive in the services they offer. Terms of the deal, which closed near ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/virtual-womens-health-company-wisp-buys-tbd-health/)

---

### ðŸ‡ºðŸ‡¸ IRA drug pricing petitions pile up at the Supreme Court

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 20:21

> Novartis is now the sixth drugmaker to bring its Inflation Reduction Act challenge to the Supreme Court as the pharma industryâ€™s yearslong court battle comes to a head. Novartis was the last drugmaker expected to ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/)

---

### ðŸ‡ºðŸ‡¸ Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 18:32

> CytoDyn's former CEO Nader Pourhassan was sentenced Friday to 30 months in prison for misleading investors about the prospects of a potential drug and then selling his personal stock in the company at artificially inflated ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/ex-cytodyn-ceo-sentenced-to-30-months-for-pump-and-dump-scheme/)

---

### ðŸ‡ºðŸ‡¸ Catalent plans to close Belgium cell therapy site

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 17:45

> Catalent plans to close a cell therapy site in Gosselies, Belgium, due to â€œchanging market dynamics and customer needs,â€ a company spokesperson confirmed to Endpoints News. The contract developer and manufacturer is considering transitioning ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/catalent-plans-to-close-belgium-cell-therapy-site/)

---

### ðŸ‡ºðŸ‡¸ Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 15:07

> Plus, news about United Therapeutics and Fortitude Biomedicines: ðŸ—ï¸ San Diego startup licenses 'DNA construction' tech: Genyro gets exclusive rights to the technology, dubbed â€œSidewinder,â€ which was developed by researchers at ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/genyro-licences-dna-builder-from-caltech-dizal-targets-hong-kong-listing/)

---

### ðŸ‡ºðŸ‡¸ UK medicines agency seized 20M illegal drugs last year, including GLP-1s

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-26 12:13

> The UKâ€™s Medicines and Healthcare products Regulatory Agency (MHRA) seized almost 20 million doses of illegally traded medicines with an estimated value of nearly Â£45 million (about $61.5 million) in 2025. This is an increase ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/uk-medicines-agency-seized-20-million-illegal-drugs-last-year-including-glp-1s/)

---

### ðŸ‡ºðŸ‡¸ Novo's Wegovy pill off to a solid start after just two weeks on market

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 20:23

> Novo Nordiskâ€™s weight loss pill is off to an impressive start after less than three weeks on the market. Prescriptions are quickly ramping up, increasing by roughly 500% in the pillâ€™s second week, analysts said ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ðŸ‡ºðŸ‡¸ FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:37
- **é‡è¦æ€§**: â­â­â­â­

> On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly)

---

### ðŸ‡ºðŸ‡¸ Oncology (Cancer)/Hematologic Malignancies Approval Notifications

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:55
- **é‡è¦æ€§**: â­â­â­â­

> FDA does not&nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&nbsp;Drugs@FDA&nbsp;for the latest approvals and prescribing information for specific products.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)

---

### ðŸ‡ºðŸ‡¸ Natural Disaster Preparedness and Response | Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 14:25
- **é‡è¦æ€§**: â­â­â­â­

> Stay informed on FDA's guidance for drugs used in natural disaster preparedness and response. Learn about emergency drug supplies, FDA-approved treatments, and safety measures for public health during disasters like hurricanes, floods, and more.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/emergency-preparedness-drugs/natural-disaster-preparedness-and-response-drugs)

---

### ðŸ‡ºðŸ‡¸ FDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice - 06/02/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:26
- **é‡è¦æ€§**: â­â­â­

> This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fdamhrahealth-canada-symposium-regulatory-perspectives-good-clinical-practice-bioequivalence-and)

---

### ðŸ‡ºðŸ‡¸ Untitled Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 20:21
- **é‡è¦æ€§**: â­â­

> These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion's untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters)

---

### ðŸ‡ºðŸ‡¸ Project Orbis

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 20:13
- **é‡è¦æ€§**: â­â­

> Information Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) that provides a framework for concurrent submission and review of oncology products among international partners.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/oncology-center-excellence/project-orbis)

---

### ðŸ‡ºðŸ‡¸ What Does FDA Approve? Part 2

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:23
- **é‡è¦æ€§**: â­â­

> The growing spread of rumors, misinformation and disinformation about science, medicine, and the FDA, is putting patients and consumers at risk. FDA is here to provide the facts.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/consumers/consumer-updates/what-does-fda-approve-part-2)

---

### ðŸ‡ºðŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:56
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ðŸ‡ºðŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 12:35
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ðŸ‡ºðŸ‡¸ Patient Listening Session Summaries

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 21:44
- **é‡è¦æ€§**: â­â­

> Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries)

---

### ðŸ‡ºðŸ‡¸ Generic Drugs Program Monthly and Quarterly Activities Report

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 18:25
- **é‡è¦æ€§**: â­â­

> Monthly and quarterly metrics of the FDA Generic Drugs Program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drugs-program-monthly-and-quarterly-activities-report)

---

### ðŸ‡ºðŸ‡¸ Biosimilar Product Information

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 18:16
- **é‡è¦æ€§**: â­â­

> This page includes a chart of the approved biosimilar and interchangeable products. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/biosimilars/biosimilar-product-information)

---

### ðŸ‡ºðŸ‡¸ Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:06
- **é‡è¦æ€§**: â­

> This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome)

---

### ðŸ‡ºðŸ‡¸ Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-26 15:04
- **é‡è¦æ€§**: â­

> This draft guidance provides guidance to sponsors and applicants submitting investigational new drug applications (INDs), new drug applications (NDAs), biologics licensing applications (BLAs), or supplemental applications on the appropriate use of Bayesian methods in clinical trials.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products)

---

### ðŸ‡ºðŸ‡¸ Patent Certifications and Suitability Petitions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:00

> Information on patents and suitability petitions that impact the availability of generic drugs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions)

---

### ðŸ‡ºðŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:25

> Generic Drug Facilities, Sites and Organization Lists

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ðŸ‡ºðŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:22

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ðŸ‡ºðŸ‡¸ Center For Immunology Science, LLC - 719933 - 01/13/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 14:20

> Sponsor/Investigator

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/center-immunology-science-llc-719933-01132026)

---

### ðŸ‡ºðŸ‡¸ Fulijaya Manufacturing SDN. BHD. - 719172 - 01/14/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 14:20

> CGMP/Finished Pharmaceuticals/Adulterated

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fulijaya-manufacturing-sdn-bhd-719172-01142026)

---

### ðŸ‡ºðŸ‡¸ Genetic Metabolic Diseases Advisory Committee (GeMDAC) Charter

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 21:18

> The Genetic Metabolic Diseases Advisory Committee (GeMDAC) advises the Commissioner of Food and Drugs or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs and biologic products for human use and as required.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/advisory-committees/genetic-metabolic-diseases-advisory-committee/genetic-metabolic-diseases-advisory-committee-gemdac-charter)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ðŸ‡ºðŸ‡¸ Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 12:05
- **é‡è¦æ€§**: â­â­

> Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/)

---

### ðŸ‡ºðŸ‡¸ ErVimmune raises 17m euros in funding to develop cancer vaccine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 14:10
- **é‡è¦æ€§**: â­â­

> The vaccine could be created as a ready-to-use product, rather than needing to be personalised

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/)

---

### ðŸ‡ºðŸ‡¸ BioMed X launches kidney disease project in partnership with the government of Barbados

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:54
- **é‡è¦æ€§**: â­

> Initiative focuses on population-specific molecular profiling

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/)

---

### ðŸ‡ºðŸ‡¸ Gedeon Richter UK takes over UK rights to cariprazine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:47

> Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/)

---

### ðŸ‡ºðŸ‡¸ Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 11:57

> Ovarian cancer is the fifth leading cause of deaths from cancer in women

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/)

---

### ðŸ‡ºðŸ‡¸ Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 12:36

> The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/)

---

### ðŸ‡ºðŸ‡¸ Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:13

> More than 71% of patients treated with Unloxcyt achieved disease control

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/)

---

### ðŸ‡ºðŸ‡¸ Peter Llewellyn-Davies

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:02

> ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/appointments/peter-llewellyn-davies/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-28 03:45:09*